Alumis Inc. $ALMS Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its holdings in Alumis Inc. (NASDAQ:ALMS) by 775.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 154,634 shares of the company’s stock after buying an additional 136,973 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.12% of Alumis worth $3,407,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Samsara Biocapital LLC increased its holdings in shares of Alumis by 19.9% during the fourth quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock valued at $56,188,000 after acquiring an additional 955,614 shares in the last quarter. Vanguard Group Inc. grew its position in Alumis by 18.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after purchasing an additional 625,404 shares during the last quarter. Cormorant Asset Management LP grew its position in Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after purchasing an additional 1,488,200 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in shares of Alumis by 11.9% during the first quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock valued at $62,360,000 after buying an additional 300,000 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of Alumis in the fourth quarter valued at about $23,443,000.

Alumis Stock Down 0.7%

NASDAQ:ALMS opened at $27.60 on Friday. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35. The stock’s 50-day moving average price is $25.62 and its 200-day moving average price is $25.26. The stock has a market capitalization of $3.52 billion, a PE ratio of -13.94 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. Sell-side analysts expect that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Alumis

In related news, insider Mark Christopher Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $67,823.64. Following the sale, the insider owned 48,533 shares of the company’s stock, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David M. Goldstein sold 2,596 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the completion of the sale, the insider directly owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. The trade was a 7.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Chardan Capital boosted their target price on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $39.00 price target on shares of Alumis in a report on Friday, May 15th. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis currently has an average rating of “Moderate Buy” and an average target price of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.